Chan, David L. http://orcid.org/0000-0002-7773-3144
Hayes, Aimee R.
Karfis, Ioannis
Conner, Alice http://orcid.org/0000-0002-1313-1582
Furtado O’Mahony, Luke
Mileva, Magdalena
Bernard, Elizabeth
Roach, Paul
Marin, Gwennaëlle
Pavlakis, Nick
Schembri, Geoffrey
Gnanasegaran, Gopinath
Marin, Clementine
Vanderlinden, Bruno
Navalkissoor, Shaunak
Caplin, Martyn E.
Flamen, Patrick
Toumpanakis, Christos
Bailey, Dale L.
Article History
Received: 4 April 2022
Revised: 26 October 2022
Accepted: 7 November 2022
First Online: 25 November 2022
Competing interests
: DLC reports honoraria from Ipsen and Novartis; and research support from EMD Serono, outside the submitted work. NP reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Serono, Ipsen, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Roche Pharma AG, Merck, Baxalta, and Specialised Therapeutics, outside the submitted work. GG reports personal fees from AAA, outside the submitted work. SN reports personal fees from AAA, outside the submitted work. MC reports personal fees from Ipsen, Novartis, AAA, Lexicon, and Pfizer, and grants from AAA and Ipsen, outside the submitted work. CT reports personal fees from Ipsen, Novartis, and AAA, education grants from Ipsen, Novartis and AAA, outside the submitted work. The remaining authors declare no competing interests.
: This study was approved by the relevant ethics committee for each centre: Northern Sydney Local Health District Human Research Ethics Committee [2019/ETH14060], the Royal Free Hospital NHS Foundation Trust Quality Governance and Clinical Audit Committee, and the Ethics Committee of Jules Bordet Institute [CE2531]. Each committee waived the need for informed consent. The study was performed in accordance with the Declaration of Helsinki.